Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 08, 2024 at 12:12: PM
via Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio.

article source
 

<



Similar threads

cafead
Eli Lilly inks OpenAI deal for discovering new antibiotics
Replies
0
Views
33
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Australia-based Telix Pharmaceuticals inks oncology deal with Eli Lilly
Replies
0
Views
106
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche
Replies
0
Views
278
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Replies
0
Views
147
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Juno inks deals with Eli Lilly as it looks to leapfrog leaders on BCMA
Replies
0
Views
295
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote